North Estonia Medical Centre

From Beacon

The North Estonia Medical Centre is one of the top healthcare providers in the country. Its statutes states that their goal is "to provide high-quality, specialized medical care and ambulance services, to be the learning base of training that precedes and follows the acquiring of health care professionals’ qualifications and does healthcare-related study and research work."

See other cancer centers in Estonia.

Trials

Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Summary: This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.

Sponsor, manager, or home institution: Agenus Inc.

Intervention/Treatment: Drug: AGEN2034

Number of patients: 211 participants

Beginning Date: April 7, 2017

Last Update: November 3, 2022

Recruitment Status: Completed.

Cancer areas of interest: Advanced Cancer and Cervical Cancer

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Summary: This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

Sponsor, manager, or home institution: Merck Sharp & Dohme LLC

Intervention/Treatment: Drug: Pembrolizumab; Radiation: Conventional Radiotherapy (Bladder only); Radiation: Conventional Radiotherapy (Bladder and pelvic nodes); Radiation: Hypofractionated Radiotherapy (Bladder only); Drug: Cisplatin; Drug: Fluorouracil (5-FU); Drug: Mitomycin C (MMC); Drug: Gemcitabine; Drug: Placebo to Pembrolizumab

Number of patients: 636 participants

Beginning Date: January 27, 2020

Last Update: October 21, 2022

Recruitment Status: Recruiting.

Cancer areas of interest: Urinary Bladder Neoplasms

Experts

Learning Resources

Cancer-related Patient Associations and Resources

Association: Patient Advisory Council

Content Type: Ensures the interests of the patient are being taken into account when making decisions and designing services, and that the patient has an active role in the treatment process.

Members: Estonian Rheumatism Association; Avitus NGO; Estonian Inflammatory Bowel Disease Society NGO; Estonian Celiac Society; Estonian Psoriasis Association; Estonian Hemophilia Society;Estonian Chamber of Disabled People; Tallinn Chamber of Disabled People; Saaremaa Cancer Society; Läänemaa Cancer Association; Estonian Stroke Patients Society.

Access: Information [1]

Service: Tobacco Cessation Counseling Office

Content Type: Trained nurses perform counseling, organize a treatment plan for the patients, and accompany them during a specific time to help them quit smoking.

Target Audience: Free for everyone.

Access: Information [2]

Service: Chemotherapy Counseling

Content Type: A nurse-counselor instructs the patient and his family individually before, during, and after the chemotherapy treatment about the procedure, possible side effects, and how to deal with those.

Target Audience: Patients and their relatives.

Access: Information [3]

Service: Palliative Care Nurse Advisor

Content Type: A nurse instructs about the disease the patient is suffering from and how to deal with it and connects the patient to specialists who will help with palliative care.

Target Audience: Patients and their relatives.

Access: Information [4]

Resource: Learning Resources for Relatives and Caretakers

Content Type: Guides and counseling appointment information.

Target Audience: Patients, Relatives and Caretakers.

Access: Information [5]